https://www.selleckchem.com/pr....oducts/ulixertinib-b
500 SPMs/4542 controls, RR 1.12, p = 0.269). Most patients were radioiodine-treated (81 %). The risk of SPMs with low cumulative radioiodine doses was RR 0.94 (≤ 3.7 GBq, p = 0.65 and with high doses RR 1.37 (3.7 GBq, p = 0.143). Cumulative radioiodine dose increased during the study period. The overall incidence of SPMs was not higher in patients than in controls. The incidence of SPMs in thyroid carcinoma patients was higher in patients 40 years old and patients diagnosed since 1996. The incidence of sa
Like
Comment
Share